DrugPatentWatch Database Preview
Details for Patent: 8,470,359
» See Plans and Pricing
Which drugs does patent 8,470,359 protect, and when does it expire?
Patent 8,470,359 protects ELIGARD KIT and FENSOLVI KIT and is included in four NDAs.
This patent has sixty-eight patent family members in twenty-six countries.
Summary for Patent: 8,470,359
| Title: | Sustained release polymer |
| Abstract: | A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months. |
| Inventor(s): | Dunn; Richard L. (Fort Collins, CO) |
| Assignee: | QLT USA, Inc. (Willmington, DE) |
| Application Number: | 11/469,392 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,470,359
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolmar Therap | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021379-001 | Jul 24, 2002 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | METHOD OF TREATING CANCER | Start Trial | ||
| Tolmar Therap | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021488-001 | Feb 13, 2003 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | METHOD OF TREATING CANCER | Start Trial | ||
| Tolmar Therap | ELIGARD KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 021731-001 | Dec 14, 2004 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | METHOD OF TREATING CANCER | Start Trial | ||
| Tolmar | FENSOLVI KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 213150-001 | May 1, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,470,359
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 259217 | Start Trial | |||
| Austria | 296088 | Start Trial | |||
| Austria | 458469 | Start Trial | |||
| Australia | 1331200 | Start Trial | |||
| Australia | 2001292931 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
